ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 45 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,817,559 | +217.3% | 246,075 | +184.9% | 0.01% | +250.0% |
| Q2 2023 | $887,935 | +180.7% | 86,375 | +110.8% | 0.00% | +100.0% |
| Q1 2023 | $316,327 | -34.0% | 40,975 | -37.1% | 0.00% | 0.0% |
| Q4 2022 | $479,036 | -2.8% | 65,175 | -4.8% | 0.00% | 0.0% |
| Q3 2022 | $493,000 | -42.9% | 68,475 | -32.6% | 0.00% | -50.0% |
| Q2 2022 | $864,000 | -15.6% | 101,575 | -11.0% | 0.00% | -33.3% |
| Q1 2022 | $1,024,000 | -31.4% | 114,175 | +5.9% | 0.00% | -25.0% |
| Q4 2021 | $1,493,000 | +235.5% | 107,775 | +158.6% | 0.00% | +300.0% |
| Q3 2021 | $445,000 | -28.6% | 41,675 | -39.8% | 0.00% | -50.0% |
| Q2 2021 | $623,000 | -53.3% | 69,175 | -45.1% | 0.00% | -50.0% |
| Q1 2021 | $1,335,000 | +3.1% | 125,975 | +22.6% | 0.00% | +33.3% |
| Q4 2020 | $1,295,000 | +100.5% | 102,775 | +39.9% | 0.00% | +50.0% |
| Q3 2020 | $646,000 | – | 73,475 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |